Bladder Cancer New Reference: Enfortumab Vedotin + Pembrolizumab for Advanced Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Protocol: Maintenance Sacituzumab Govitecan with Avelumab for Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Indication: Neoadjuvant Durvalumab with CISplatin/Gemcitabine for Upper GU Tract Cancer Ulas D. Bayraktar, MD 2025-05-05
Bladder Cancer New Reference: Sacituzumab Govitecan for Advanced Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-04-07
Bladder Cancer New Indication: Adjuvant Pembrolizumab for Bladder Cancer Ulas D. Bayraktar, MD 2025-03-31
Bladder Cancer New Indication: Erdafitinib in Advanced FGFR Altered Urothelial Cancer Ulas D. Bayraktar, MD 2023-11-20
Bladder Cancer New Indication: Durvalumab with CISplatin and Gemcitabine in Biliary Tract Cancers Ulas D. Bayraktar, MD 2023-06-14
Bladder Cancer New Indication: Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma Ulas D. Bayraktar, MD 2023-06-07
Bladder Cancer New Protocol: Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer Ulas D. Bayraktar, MD 2023-04-14
Bladder Cancer New Reference: Neoadjuvant CISplatin and Gemcitabine for Urothelial Cancer Ulas D. Bayraktar, MD 2023-03-15
